icon- folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020
 		Back grey_arrow_rt.gif
 
 
 
CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY DOSING: WEEK 48 RESULTS FROM THE ATLAS-2M STUDY
 
 
  Edgar T. Overton1

0320201

0320202

0320203

0320204

0320205

0320206

0320207